Image Credit: depositphotos.com
A decade-long clinical trial involving nearly 10,000 adults aged 70 and older has demonstrated that daily use of statins can reduce the risk of a first major cardiac event by 30%. The study, which was published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress, is the first randomized controlled trial to specifically assess the preventive effects of statins in otherwise healthy seniors.
Conducted by researchers from Monash University in Australia, the trial addressed a significant gap in cardiovascular research, as older adults have been largely excluded from prior studies shaping current prescribing guidelines. Historically, heart disease research focused on younger populations, particularly middle-aged smokers. As the population ages, the need for effective preventive measures for older adults has become increasingly urgent.
The trial involved collaboration with approximately 3,400 general practitioners across Australia. Participants who had conditions contraindicating statin use, those not living independently, and individuals with a history of heart attacks were excluded from the study. Participants were randomly assigned to receive either a daily statin or a placebo. Over the nearly six-year duration of the trial, findings indicated that one major cardiovascular event, such as a heart attack or stroke, could be prevented for every 37 adults treated.
Importantly, the study found no significant increase in dementia rates among those taking statins compared to the placebo group, alleviating concerns that have led some older patients to avoid these medications. However, while statins effectively reduced the occurrence of cardiac events, the trial did not show improvements in disability-free survival, suggesting that while cardiovascular risks can be mitigated, other age-related health challenges persist.
Despite the promising results, the trial’s demographic was predominantly white, with an average age of 75, raising questions about the generalizability of the findings across diverse populations. Additionally, more than 15% of participants discontinued their medication during the trial.
The lead researchers hope that this evidence will lead to updated prescribing guidelines for statins in older adults, facilitating better decision-making for healthcare providers and their patients.
Check out the original article here: Source link
